Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Clinical trial NCT02307812 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT02307812
- Sponsor
- Eli Lilly and Company
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.